Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Forte Biosciences (FBRX) Consolidated Net Income (2016 - 2020)

Forte Biosciences (FBRX) has disclosed Consolidated Net Income for 5 consecutive years, with -$4.5 million as the latest value for Q4 2020.

  • Quarterly Consolidated Net Income rose 57.55% to -$4.5 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was -$47.0 million through Dec 2020, up 0.74% year-over-year, with the annual reading at $3.1 million for FY2025, 108.77% up from the prior year.
  • Consolidated Net Income for Q4 2020 was -$4.5 million at Forte Biosciences, up from -$5.0 million in the prior quarter.
  • The five-year high for Consolidated Net Income was -$383000.0 in Q3 2018, with the low at -$34.8 million in Q2 2020.
  • Average Consolidated Net Income over 5 years is -$10.8 million, with a median of -$9.1 million recorded in 2017.
  • The sharpest move saw Consolidated Net Income skyrocketed 96.15% in 2018, then tumbled 4791.64% in 2019.
  • Over 5 years, Consolidated Net Income stood at -$8.5 million in 2016, then dropped by 28.08% to -$10.8 million in 2017, then tumbled by 80.89% to -$19.6 million in 2018, then soared by 46.01% to -$10.6 million in 2019, then soared by 57.55% to -$4.5 million in 2020.
  • According to Business Quant data, Consolidated Net Income over the past three periods came in at -$4.5 million, -$5.0 million, and -$34.8 million for Q4 2020, Q3 2020, and Q2 2020 respectively.